Jefferies analyst Eun Yang views the post-Phase 2 data selloff today in shares of RA Pharmaceuticals (RARX) as overreaction. The interim data show RA’s RA101495 is an active and approvable product with efficacy as good as Alexion’s (ALXN) Soliris, Yang tells investors in an intraday research note. While RA101495 may not be suitable for the 20% of Soliris patients that are transfusion dependent, the 37% selloff in the stock today is “way too overdone,” the analyst contends. Yang sees “significant upside potential” in RA shares even at “modest market share of Soliris.” She keeps a Buy rating on RA Pharmaceuticals with a $25 price target. The stock in midday trading is down $5.34 to $8.89.